-+ 0.00%
-+ 0.00%
-+ 0.00%

Lantern Pharma's Starlight Therapeutics Receives FDA Clearance Its IND For Phase Ib/2a Glioblastoma Multiforme Trial

Benzinga·08/06/2025 12:32:51
Listen to the news
  • Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression
  • GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number of cases globally
  • Lantern Pharma has previously received both FDA Orphan and Fast Track Designations in GBM